FDA Updates SMA Treatment Dosing - Quiz - MDSpire

FDA Updates SMA Treatment Dosing

A higher-dose nusinersen regimen for spinal muscular atrophy demonstrated statistically significant motor function improvement in treatment-naïve infants in the DEVOTE trial with a safety profile consistent with prior dosing.

  • By

  • Kathryn Wighton

  • March 30, 2026

  • 2 min

Share

Original Source(s)

FDA Updates SMA Treatment Dosing

  • by Kathryn Wighton

  • March 30, 2026

Related Content

Opportunities and Concerns of Gamified, Extended Reality for Home-Based Motor Rehabilitation for Children With Brain Injury: Qualitative Case Study on Design Elements Related to the Engagement and Fatigue Perspectives

Does Sedative Choice Shape Later Cognition?

Researchers examined long-term cognitive outcomes among children who received ICU sedation for acute respiratory failure.

Treatment non-persistence in children and adolescents with Tourette syndrome newly treated with dopamine D2 receptor modulators